
Oncternal Therapeutics ONCT
Quarterly report 2024-Q3
added 05-16-2026
Oncternal Therapeutics Interest Expense 2011-2026 | ONCT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Oncternal Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 33 K | 317 K | -1.08 M | 1 K | 122 K | 46 K | 57 K | -259 K | 1.49 M | -19 K | 398 K | 1.36 M | 188 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.49 M | -1.08 M | 204 K |
Quarterly Interest Expense Oncternal Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 K | 13 K | 13 K | - | 1 K | 1 K | 139 K | 171 K | 196 K | 143 K | 131 K | 122 K | 27 K | 40 K | 27 K | - | 13 K | 5 K | 28 K | -4 K | 9 K | 25 K | 27 K | -284 K | 21 K | 2 K | 2 K | 1.39 M | 23 K | 21 K | 55 K | -33 K | -47 K | 53 K | 8 K | 66 K | 23 K | 7 K | 302 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.39 M | -284 K | 74.3 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 16.87 | -2.49 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
10.1 M | $ 7.47 | -4.6 % | $ 205 M | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Eton Pharmaceuticals
ETON
|
1.06 M | $ 30.26 | 1.0 % | $ 814 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Exelixis
EXEL
|
-198 K | $ 50.13 | -1.9 % | $ 13.6 B | ||
|
Fortress Biotech
FBIO
|
17.6 M | $ 2.41 | 4.78 % | $ 67.2 M | ||
|
Forte Biosciences
FBRX
|
-396 K | $ 23.11 | -3.55 % | $ 299 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.63 | 2.52 % | $ 434 M | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 89.55 | -2.65 % | $ 21.6 B | ||
|
Galectin Therapeutics
GALT
|
1.03 M | $ 2.17 | -7.66 % | $ 139 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Gilead Sciences
GILD
|
-1 M | $ 129.58 | -1.88 % | $ 161 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.36 | -3.72 % | $ 5.53 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 M | $ 0.72 | -1.58 % | $ 32.9 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 3.12 | - | $ 649 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M |